share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/17 17:03
Moomoo AI 已提取核心訊息
Applied UV, Inc. has reported a notice of non-compliance with Nasdaq Listing Rule 5605, received on May 15, 2024, due to the resignation of Eugene Burleson from the Board of Directors, leaving the Audit Committee with only two independent directors instead of the required three. The company, headquartered in Mount Vernon, NY, is listed on The Nasdaq Stock Market LLC with common stock under the symbol AUVI and 10.5% Series A Cumulative Perpetual Preferred Stock under AUVIP. Applied UV has been granted a cure period until the earlier of its next annual shareholders' meeting or May 7, 2025, to resolve the issue, with a deadline of November 4, 2024, if the annual meeting occurs before that date. The company plans to elect an additional independent director to the Audit Committee within this timeframe. This event has not affected the trading of Applied UV's common stock on The Nasdaq Capital Market. Additionally, on May 14, 2024, Christopher Kochuba was appointed to the Audit Committee and compensation committee of the Board.
Applied UV, Inc. has reported a notice of non-compliance with Nasdaq Listing Rule 5605, received on May 15, 2024, due to the resignation of Eugene Burleson from the Board of Directors, leaving the Audit Committee with only two independent directors instead of the required three. The company, headquartered in Mount Vernon, NY, is listed on The Nasdaq Stock Market LLC with common stock under the symbol AUVI and 10.5% Series A Cumulative Perpetual Preferred Stock under AUVIP. Applied UV has been granted a cure period until the earlier of its next annual shareholders' meeting or May 7, 2025, to resolve the issue, with a deadline of November 4, 2024, if the annual meeting occurs before that date. The company plans to elect an additional independent director to the Audit Committee within this timeframe. This event has not affected the trading of Applied UV's common stock on The Nasdaq Capital Market. Additionally, on May 14, 2024, Christopher Kochuba was appointed to the Audit Committee and compensation committee of the Board.
Applied UV, Inc. 報告說，由於尤金·伯勒森辭去董事會職務，審計委員會只有兩名獨立董事，而不是規定的三名，因此於2024年5月15日收到一份關於不遵守納斯達克上市規則5605的通知。該公司總部位於紐約州弗農山，在納斯達克股票市場有限責任公司上市，普通股代碼爲AUVI，A系列累積永久優先股以AUVIP命名，10.5％的A系列累積永久優先股。如果年會在此日期之前舉行，Applied UV已獲准在下次年度股東大會或2025年5月7日之前解決該問題的治癒期，截止日期爲2024年11月4日。公司計劃在這段時間內爲審計委員會增選一名獨立董事。該事件並未影響應用紫外光普通股在納斯達克資本市場的交易。此外，克里斯托弗·科丘巴於2024年5月14日被任命爲董事會審計委員會和薪酬委員會成員。
Applied UV, Inc. 報告說，由於尤金·伯勒森辭去董事會職務，審計委員會只有兩名獨立董事，而不是規定的三名，因此於2024年5月15日收到一份關於不遵守納斯達克上市規則5605的通知。該公司總部位於紐約州弗農山，在納斯達克股票市場有限責任公司上市，普通股代碼爲AUVI，A系列累積永久優先股以AUVIP命名，10.5％的A系列累積永久優先股。如果年會在此日期之前舉行，Applied UV已獲准在下次年度股東大會或2025年5月7日之前解決該問題的治癒期，截止日期爲2024年11月4日。公司計劃在這段時間內爲審計委員會增選一名獨立董事。該事件並未影響應用紫外光普通股在納斯達克資本市場的交易。此外，克里斯托弗·科丘巴於2024年5月14日被任命爲董事會審計委員會和薪酬委員會成員。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息